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Metastasis occurs when genetically unstable cancer cells adapt to a tissue microenviron-
ment that is distant from the primary tumor. This process involves both the selection of traits 
that are advantageous to cancer cells and the concomitant recruitment of traits in the tumor 
stroma that accommodate invasion by metastatic cells. Recent conceptual and technological 
advances promote our understanding of the origins and nature of cancer metastasis.How tumors spread and kill their host organism remains 
an enigma, but not for lack of attention. For more than a 
century, cancer biologists have postulated that metas-
tasis results from the interplay of wandering tumor cells 
with permissive target tissues. Yet, decades of scrutiny 
into the molecular bases of cancer have largely focused 
on what causes oncogenic transformation and the incip-
ient emergence of tumors. By comparison, the study of 
how tumor cells take steps toward metastasis (that is, by 
altering their microenvironment, entering the circulation, 
and colonizing a distant organ) has received less atten-
tion. Progressively, however, the idea has emerged that 
tumors are more than just a mass of transformed cells. 
A renewed focus on the problem of metastasis is now 
apparent, and for good reason—metastasis remains the 
cause of 90% of deaths from solid tumors.
Several developments point toward progress. Recent 
work suggests that certain oncogenic events, such as 
evasion of growth suppression or of DNA-damage check-
points, may also contribute to the evolution of tumors 
to the metastatic state because they create genomic 
instability. With increasing resolution, the genetic and 
epigenetic aberrations in tumors and their surrounding 
stroma are being profiled genomewide in both animal 
models and clinical samples. New evidence points at the 
engagement of cellular accomplices from the stroma to 
aid in tumor-cell survival and parasitic dominance at dis-
tant organ sites. Molecular mediators of tumor-cell hom-
ing to and colonization of specific organ sites are also 
beginning to emerge. Recent technological advances 
allow validation of these new findings through the analy-
sis of clinical samples. Taking stock of these develop-
ments may help in the creation of a roadmap to guide 
future work.
A Problem of Evolution
An underlying concept in our analysis is that metastasis 
emerges from the somatic evolution of a genetically diver-
sified cancer-cell population under the selective pressures 
of an environment that imposes tight rules on cell behav-
ior. In essence, this explains why millions of cells might be released by a tumor into the circulation every day, but only 
a tiny minority of these cells will colonize a distant organ. 
The utter inefficiency of the metastatic process implies 
that healthy tissues display a marked hostility toward 
invading tumor cells. This is not surprising. In a highly 
evolved organism, homeostatic mechanisms ensure that 
order is maintained in its tissues. To achieve metastasis, 
cancer cells must therefore evade or co-opt multiple rules 
and barriers that were refined over hundreds of millions of 
years of organismal evolution. Thus, metastasis is akin to 
an evolutionary process that involves selection of geneti-
cally heterogeneous lineages of cancer cells within the 
ecosystem of an organism.
Several discrete steps are discernable in the biologi-
cal cascade of metastasis: loss of cellular adhesion, 
increased motility and invasiveness, entry and survival 
in the circulation, exit into new tissue, and eventual 
colonization of a distant site (Chambers et al., 2002; 
Fidler, 2003). Seminal work using experimental assays 
for metastasis demonstrated that rare clones within 
malignant cell populations were endowed with several 
of these metastasis-promoting functions (Fidler, 2003). 
The implication was that cells that comprise a metastatic 
lesion were descendants of an exceedingly rare cell from 
the primary tumor that stochastically expressed many, if 
not all, of the genes necessary for successful execution 
of the metastatic cascade (Fidler, 2003).
Recent advances in the molecular profiling of cancer 
using genomic-level approaches have revealed genes 
whose expression in primary tumors correlates strongly 
with the likelihood of metastatic recurrence (Weigelt et al., 
2005). These observations have also prompted a recon-
sideration of how, where, and when cancer cells acquire 
genes of relevance to metastasis and have raised the pos-
sibility that cells with metastatic potential may not be as 
rare in primary tumors as was originally believed (Bernards 
and Weinberg, 2002). Furthermore, recent evidence under-
scores the profound impact that the transformed cell of ori-
gin has on the metastatic course of a tumor—an important 
concept that conventional models for the selective evolu-
tion of cancers did not fully appreciate.Cell 127, November 17, 2006 ©2006 Elsevier Inc. 679
Although developments such as these reflect the 
complexity of cancer progression, they do not detract 
from the idea that metastatic cells must overcome 
numerous physical obstacles barring metastasis. The 
common biological challenges posed by these barri-
ers suggest that there might be recurrent themes for 
metastatic progression, just as there are for primary 
tumor formation (Figure 1). In this way, cancer may 
progress as a disease of genetically heterogeneous 
cell populations driven to evolve by sequential envi-
ronmental pressures.
Figure 1. Stages of Metastatic Progression
Metastasis proceeds through the progressive acquisition of traits that 
allow malignant cells originating in one organ to disseminate and colo-
nize a secondary site. Although these traits are depicted as part of 
a contiguous biological sequence, their acquisition during metastatic 
progression need not follow this particular order. Although in some 
cases several factors may be necessary to implement a single step in 
this cascade, other mediators of metastasis may facilitate execution 
of multiple stages simultaneously. Similarly, the specific steps of this 
sequence that are rate limiting for metastatic progression may also 
vary from one tumor to the next.680 Cell 127, November 17, 2006 ©2006 Elsevier Inc.The Early Origin of Cellular Heterogeneity
Evolutionary processes require a source of heterogene-
ity within the population, from which advantageous traits 
can be selected. In the context of a tumor, this hetero-
geneity is amply supplied by the intrinsic instability of 
cancer genomes in the form of DNA mutations, chro-
mosomal rearrangements, and epigenetic alterations. 
Evidence that highly metastatic clones from tumor-cell 
populations had a higher rate of genetic mutability than 
nonmetastatic clones from the same tumor provided 
an early link between metastasis and genetic instability 
(Fidler, 2003).
Major alterations in genomic DNA were once viewed 
as an exclusive trait of advanced cancers. However, it is 
now recognized that DNA damage and genomic instabil-
ity are underlying features of human cancer from the ear-
liest stages of tumorigenesis. Damage to genomic DNA 
is evident even in apparently normal cells and becomes 
amplified as tumors emerge (Bartkova et al., 2005; 
Feinberg et al., 2006; Gorgoulis et al., 2005). Genomic 
instability may be directly driven by mutations leading to 
tumor initiation that were once thought to cause abnor-
mal cell proliferation but not much else. For example, 
inactivation of the cell cycle suppressor Retinoblastoma 
(Rb) alters the expression of the mitotic checkpoint 
regulator Mad2, which fosters aneuploidy (Hernando et 
al., 2004). Hyperactive mediators of oncogenic signal-
ing such as Akt can attenuate the DNA-damage check-
point response by disabling damage sensors such as 
the kinase Chk1 (Puc et al., 2005). Telomeric crisis may 
wreak havoc on the genomes of cancer cells, produc-
ing a myriad of traits associated with tumor progression 
(Maser and DePinho, 2002). Moreover, epigenetic plas-
ticity must be recognized as an important source of can-
cer-cell heterogeneity (Baylin and Ohm, 2006; Feinberg 
et al., 2006). As a recent example, ectopic overexpres-
sion of the polycomb group protein EZH2, which results 
in alterations in chromatin remodeling, correlates with 
metastasis and poor overall survival in prostate cancer 
patients (Varambally et al., 2002).
Pressures that Select for an Aggressive Phenotype
The inappropriate proliferation of cells harboring onco-
genic lesions is challenged by multiple layers of mecha-
nisms that suppress tumor formation (Figure 2). Several 
of these barriers are cell intrinsic (such as the genotoxic 
stress induced by oncogenes, the expression of growth 
inhibitory, apoptotic and senescence pathways, and 
telomere attrition). Evasion of these tumor suppressive 
pathways is a hallmark of primary tumors (Hanahan and 
Weinberg, 2000). However, an entirely distinct class of 
pressures comes from sources that are extrinsic to the 
cancerous cells. Factors in the tumor microenvironment 
that limit tumor progression include extracellular matrix 
components, basement membranes, reactive oxygen 
species, the limited availability of nutrients and oxy-
gen, and attack by the immune system (Figure 2). How 
tumors cells respond to these external cues influences, 
sometimes in dramatic fashion, 
their metastatic potential. An 
example is provided by the cel-
lular response to hypoxia, which 
is emerging as a major player 
that shapes the aggressiveness 
of primary tumors.
In tumors, hypoxia is a strong 
selective pressure that promotes 
the outgrowth of malignant cells 
with a diminished susceptibility 
to undergo apoptosis. The cellu-
lar response to low oxygen ten-
sion involves the stabilization of a 
hypoxia inducible factor-1 (HIF-1) 
transcriptional complex that acti-
vates genes that promote angio-
genesis, anaerobic metabolism, 
cell survival, and invasion (Harris, 
2002). Tumors that exhibit abun-
dant HIF-1 stabilization have a 
greater likelihood of developing 
metastatic relapse and corre-
late with a shorter survival time 
(Semenza, 2003). Accordingly, 
by analyzing global transcript 
levels an “epithelial cell hypoxia 
signature” has been established 
that is an independent predictor 
of metastatic risk for both breast 
and ovarian carcinomas (Chi et 
al., 2006). A subset of HIF-1 tar-
get genes may act as mediators 
of metastatic progression. HIF-
1 induces the expression of the 
chemokine receptor CXCR4 in 
renal cell carcinoma cells, which 
may promote organ-specific 
metastatic dissemination (Staller 
et al., 2003). A recent study 
implicates lysyl oxidase (LOX) 
as a HIF-1 target that mediates 
metastasis of human breast can-
cer cells in a mouse model and 
correlates with poor overall sur-
vival among estrogen receptor-
negative breast cancer patients 
(Erler et al., 2006). LOX is required for the maturation 
of newly synthesized collagen fibrils and may promote 
metastasis through changes in focal adhesion kinase 
activity. Hypoxia can also induce expression of Met, 
thereby facilitating tumor cell invasion mediated by HGF 
(the ligand for Met) (Pennacchietti et al., 2003).
Other aspects of the microenvironment may also drive 
the selective evolution of primary tumors. For instance, 
reactive species of nitrogen and oxygen, which are gen-
erated by both infiltrating inflammatory cells and rapidly 
proliferating tumor cells, can contribute to the genomic 
instability of cancer cells and 
promote the expression of genes 
that facilitate metastasis (Hus-
sain et al., 2003). Tumors also 
exert different physical pressures 
than well-organized tissues. For 
example, tensional forces on 
mammary epithelial cells dur-
ing tumorigenesis may result in 
clustering of mechanotransduc-
ing integrins and subsequent 
downstream activation of ERK 
and Rho-GTPase (Paszek et al., 
2005). These signaling events 
promote tumor-cell proliferation 
and disrupt tissue polarity.
Prerequisites for Metastasis
Tumor-Initiating Capacity
Normal cells constitute lineages 
that extend from stem cells to 
terminally differentiated progeny. 
Stem cells have the capacity to 
divide with at least one daugh-
ter retaining the phenotype of 
the mother. Similarly, the long-
term tumorigenic potential of 
some tumors may rely on a small 
proportion of malignant cells 
endowed with a similar capacity 
to indefinitely self renew. These 
tumor-initiating cells are some-
times referred to as cancer stem 
cells (Pardal et al., 2003). As was 
originally demonstrated for hema-
tological malignancies (Bonnet 
and Dick, 1997), solid malignan-
cies of the breast and brain have 
recently been shown to contain 
cells with such tumor-initiating 
capacity (Al-Hajj et al., 2003; 
Singh et al., 2004). When isolated, 
these cells were capable of giving 
rise to all other transformed cel-
lular phenotypes (as defined by 
cell surface markers) observed 
in the original tumor. Additionally, 
they were capable of initiating secondary tumors from 
very low numbers of transplanted cells (a surrogate for 
self-renewal activity). However, the idea that self renewal 
in solid tumors is a property of only a tiny cell subpopu-
lation in a tumor mass is currently supported by limited 
evidence. Moreover, if self-renewing tumor cells are the 
only cells capable of generating secondary growths, then 
one might expect that the prevalence of tumor-initiating 
cells in a tumor would reflect the overall proclivity for met-
astatic recurrence. This, however, has yet to be shown. 
Regardless of the relative abundance of self-renewing 
Figure 2. Pressures that Drive Selection for 
Metastatic Traits
Cell-intrinsic mechanisms limit the aberrant hyper-
proliferation of normal cells. Bypass of these cellular 
restraints, in part fueled by genomic and epigenomic 
instabilities, is a hallmark of cancer. The local micro-
environment provides extrinsic barriers that are evolu-
tionarily conserved to preserve normal tissue structure 
and function. These barriers can be broadly classified 
as chemical, physical, or biological in nature. Exam-
ples for each category are provided. These extrinsic 
barriers limit the outgrowth of tumors at the primary 
site, but a related set of barriers also challenges the 
intrusion of disseminated cancer cells into a second-
ary organ. As tumors evolve, these pressures drive the 
selection for traits that enable cancerous cells to by-
pass them. Tumors with limited cellular heterogeneity 
may be unable to overcome these pressures and may 
spontaneously regress or subsist in balance with these 
tumor suppressive forces. Alternatively, in tumors con-
taining a high degree of cellular heterogeneity, aggres-
sive cellular subpopulations that can resist, co-opt, or 
overcome these barriers may dominate the cancer, 
rendering it primed for metastatic progression.Cell 127, November 17, 2006 ©2006 Elsevier Inc. 681
cells in primary tumors, a capacity for tumor initiation is a 
must for the reestablishment of the tumor by a few surviv-
ing cells in a distant metastatic location.
What then are the molecular mechanisms that bestow 
upon cancer cells the ability to initiate tumors? Some 
answers to this question are beginning to emerge. The 
polycomb family protein Bmi-1, a transcriptional repres-
sor, mediates both self renewal in normal hematopoietic 
and neural stem cells, as well as tumor-initiating capacity 
among “leukemic stem cells” (Valk-Lingbeek et al., 2004). 
The Wnt/β-catenin, Hedgehog, and Notch signaling path-
ways are also implicated in stimulating self renewal in both 
normal stem cells and malignant cells (Beachy et al., 2004; 
Radtke and Clevers, 2005). Genetic alterations that acti-
vate otherwise normal self-renewing mechanisms may 
enhance metastatic efficiency. For example, overexpres-
sion of the transcriptional effector of Hedgehog signal-
ing, Gli1, in rat prostatic carcinoma cells rendered them 
aggressively metastatic to the lungs (Karhadkar et al., 
2004). For this reason, targeting these pathways in can-
cer raises concerns about possible toxicity to normal stem 
cells. However, the recent finding that hyperactive Akt sig-
naling is necessary for leukemia-initiating capacity but is a 
deterrent of hematopoietic stem-cell renewal exemplifies a 
promising opportunity for targeting malignant self renewal 
while sparing host stem cells (Yilmaz et al., 2006).
Altered Cellular Adhesions
Compared to normal epithelia, carcinoma cells almost 
invariably show diminished intercellular adhesiveness 
(Cavallaro and Christofori, 2004). In many instances, epi-
thelial tumors lose E-cadherin-mediated adhesions as they 
progress toward malignancy. Documented mechanisms 
for E-cadherin loss in tumors include inactivating muta-
tions that predispose to gastric cancer, epigenetic silenc-
ing, proteolytic cleavage, and proteosomal degradation 
(Cavallaro and Christofori, 2004). Additionally, E-cadherin 
expression can be repressed as part of a broader program 
resembling an epithelial-to-mesenchymal transition (EMT). 
EMT can occur in cancer cells upon activation of specific 
transcription factors (such as Snail, Twist, and Slug), many 
of which are involved in EMT during embryogenesis.
Integrins are also emerging as important mediators 
of the malignant phenotype during oncogenic transfor-
mation (Guo and Giancotti, 2004). In particular, the α6β4 
integrin, which binds to the extracellular matrix pro-
tein laminin, forms signaling complexes with oncogenic 
receptor tyrosine kinases, including Met, EGFR, and Her2 
(Guo and Giancotti, 2004). αVβ3 and α3β1 integrins have 
also been implicated in later stages of metastasis, spe-
cifically during adhesion of circulating tumor cells to the 
vasculature (Felding-Habermann et al., 2001; Wang et al., 
2004). Thus, diverse alterations in adhesive properties 
allow cancer cells to disobey the rules of tissue architec-
ture and to advance in their malignant progression.
Cell Motility
Metastasis fundamentally involves the movement of 
cells from one site to another. A molecular depiction 
of cell migration in in vitro models has emerged, which 682 Cell 127, November 17, 2006 ©2006 Elsevier Inc.involves dynamic cytoskeletal changes, cell-matrix inter-
actions, localized proteolysis, actin-myosin contractions, 
and focal contact disassembly (Friedl and Wolf, 2003). 
Nodes of regulation include small GTPases (such as 
Rho, cdc42, and Rac), integrin-containing focal adhe-
sion assembly and disassembly, secreted and plasma 
membrane-tethered proteases, and the actomyosin con-
tractile machinery. Growth-factor signaling, such as that 
mediated by HGF through the Met receptor, can modulate 
many of these activities either directly or indirectly (Liotta 
and Kohn, 2001). Several recent studies have implicated 
components of this cell motility machinery in metastatic 
progression. Comparative genomic analysis of in vivo 
selected melanoma cell lines in mice revealed a role for 
RhoC in lung metastasis (Clark et al., 2000). Comparative 
oncogenomic analysis of a mouse model of melanoma 
has shown that an increase in copy number and overex-
pression of Nedd9, a focal adhesion kinase (FAK) adap-
tor protein, fosters cell motility and invasion (Kim et al., 
2006). Nedd9 was also independently identified as one of 
a set of genes that mediate the metastasis of breast can-
cer to the lungs (Minn et al., 2005a). Podoplanin, a mucin-
like transmembrane glycoprotein that is expressed at the 
invasive front of many human malignancies, enhances 
cellular invasiveness independently of E-cadherin loss, 
perhaps by regulating the cytoskeletal anchoring protein 
Ezrin (Wicki et al., 2006).
Recent advances in intravital imaging of primary 
tumors in mice have uncovered properties of cancer-cell 
movement in vivo that differ from those that were origi-
nally observed in vitro. Malignant cells in breast cancers 
move much faster than similarly transformed cells on 
tissue-culture plastic or in reconstituted extracellular 
matrix (Condeelis and Segall, 2003). The faster mobility 
in vivo appears to involve the ability of malignant can-
cer cells to rapidly track along collagenous extracellular 
matrix fibers. Intriguingly, acquisition of this motile prop-
erty coincides with manifestation of the metastatic phe-
notype (Condeelis and Segall, 2003). Confirming the rel-
evance of this prometastatic motile behavior to human 
cancer and dissecting the pathways that underlie it are 
important avenues for future research.
Resistance to Extracellular Death Signals
Although evasion of apoptosis is a hallmark of tumor 
cells, it is possible that progression toward metastasis 
requires a further defense against microenvironmental 
death stimuli. Nutrient deprivation and hypoxia, altera-
tions in extracellular adhesions, changes in cell shape 
during invasion, and exposure to novel stromal micro-
environments can all trigger cell death. Ectopic over-
expression of potent anti-apoptotic effectors, such 
as BCL2, BCL-XL, and XIAP, in cancer cells can make 
them highly resistant to death stimuli, which has been 
shown to enhance the efficiency of metastasis in numer-
ous experimental models (Mehlen and Puisieux, 2006). 
Alternatively, loss of caspase 8 expression, an apoptotic 
initiator caspase activated downstream of unligated 
integrins, can also facilitate invasion and metastasis by 
making tumor cells more resistant to stress from loss 
of adhesion (Stupack et al., 2006). Pediatric neuroblas-
tomas with evidence for genomic loss at the caspase 
8 locus are commonly associated with a poor overall 
prognosis (Brodeur, 2003).
Disruption of the Basement Membrane and 
Extracellular Matrix
Basement membranes that underlie epithelial and 
endothelial cell layers are a dense meshwork composed 
of several glycoproteins and proteoglycans (such as 
type IV collagen, laminin, perlecan). A well-organized 
basement membrane is an integral contributor to epithe-
lial structure, providing both a physical boundary as well 
as a signaling substrate to orient cells through integrin-
based adhesions. For epithelial tumors in an incipient 
state, the basement membrane acts as a barrier to the 
invasion of transformed cells into the subjacent stroma. 
Tumor cells that are able to proteolytically disrupt the 
basement membrane can progress to overt malignancy 
and metastasis.
The activity of extracellular matrix proteases is nor-
mally under tight control through specific localization, 
autoinhibition, and secreted tissue inhibitors (reviewed 
in Egeblad and Werb [2002] and Liotta and Kohn [2001]). 
Cancerous cells use diverse mechanisms to disrupt this 
tight regulation and unleash proteolytic activities on the 
basement membrane and interstitial extracellular matri-
ces. In addition to facilitating tumor invasion, extracel-
lular proteases may generate a diverse array of bioactive 
cleaved peptides. These products can modulate migra-
tion, cancer-cell proliferation and survival, and tumor 
angiogenesis. Adding complexity, some of the pleio-
tropic effects of matrix metalloproteinases (MMPs) may 
actually antagonize tumor growth (Overall and Kleifeld, 
2006). The physiological importance of MMPs is evident 
by the extensive joint disorders caused by MMP inhibi-
tors in clinical trials, which has so far deterred the effec-
tive use of these agents in anticancer therapy (Coussens 
et al., 2002). Segregating the pro- versus antimetastatic 
component activities of extracellular proteases during 
different stages of cancer progression will be instrumen-
tal in designing a new generation of specific protease 
inhibitors that may be more clinically effective than the 
initial unsuccessful efforts.
Beyond the Basement Membrane: Enemies and 
Accomplices
Progression of invasive carcinomas requires collusion 
between tumor cells and multiple nontransformed cell 
types residing in (or being recruited to) the tumor stroma 
(Figure 3). Indeed, several histopathological markers of 
stromal cell cooption in tumors, such as fibrosis, leuko-
cytic infiltration, angiogenesis, and lymphangiogenesis, 
are frequently correlated with an increased likelihood 
of metastatic relapse. It could be that tumor cells that 
can convert reactive stromal infiltrates from preservers 
of homeostasis into accomplices in malignancy earn a 
selective advantage in the primary tumor and at sites of metastasis. An area of intense interest, the topic of stro-
mal contributions to cancer, has been covered by several 
recent reviews (Condeelis and Pollard, 2006; de Visser 
et al., 2006; Kalluri and Zeisberg, 2006). Here, we will 
discuss specific examples of this crosstalk that highlight 
its potential influence on the evolution of cancer toward 
metastatic competency.
As tumors evolve, are there driving forces that select 
for accommodating traits in the cancer-associated 
stroma? Heterotypic interactions between epithelial and 
mesenchymal cells are essential for proper morphogen-
esis during embryo development. For decades, cancer 
biologists have suspected that these same interactions 
could enhance the malignant phenotype of carcinomas. 
Targeted disruption of transforming growth-factor β 
(TGFβ) signaling in fibroblasts can induce carcinomas 
of the forestomach and prostate in mice (Bhowmick 
et al., 2004). Although this phenomenon has yet to be 
observed in human cancer, it provides a striking exam-
ple of the malignant potential that arises from the dis-
ruption of tumor-suppressive crosstalk. Studies using 
a transgenic mouse model for prostate cancer provide 
another intriguing example (Hill et al., 2005). Crossing 
these tumor-prone mice to mice heterozygous for p53 
led to a loss of heterozygosity and a growth advantage 
in tumor-associated fibroblasts before any such events 
Figure 3. Distinct Fates for Disseminated Cancer Cells 
Advanced malignancies are frequently coinhabited by different stro-
mal cell types. The tumor-suppressive activities of lymphocytes (T, B, 
and NK cells) are kept in check in part through the release of immuno-
suppressive cytokines (e.g., TGFβ, IL-10, and IL-23). Carcinoma-as-
sociated fibroblasts (CAFs) can secrete factors that promote tumor-
cell growth and invasiveness and also promote angiogenesis through 
recruitment of endothelial precursor cells (EPCs) from circulation. Ac-
tivated macrophages are also recruited to tumors and release many 
protumorigenic growth factors. Additionally, there is evidence that 
macrophages may comigrate with cancer cells within tumors through 
a paracrine growth-factor loop. Once cancer cells have invaded the 
blood stream, many of them will die from stresses associated with 
circulatory passage. Those that are able to resist death may attach 
to capillaries within a secondary organ through adhesion receptors, 
which may in addition provide survival signals. Subsequently, dis-
seminated cancer cells may or may not thrive at the secondary site, 
with or without metastatic extravasation.Cell 127, November 17, 2006 ©2006 Elsevier Inc. 683
were evident in the tumor epithelium. Mutations in p53 
have also been observed in the cancer-associated 
stroma of human breast tumors (Kurose et al., 2002). 
Other studies have described PTEN mutations and epi-
genetic alterations in cancer-associated stroma (Hu et 
al., 2005; Kurose et al., 2002). However, further work will 
be necessary to establish whether loss of p53 and PTEN 
functions in the stroma provide an advantage to the 
adjacent tumor cells that goes beyond effects on tumor-
associated stromal cells.
Does the recruitment of tumor-promoting mesen-
chyme confer properties to an evolving cancer that 
promote metastasis? Evidence suggests that this may 
be the case. A gene expression signature of fibroblast 
activation in vitro was able to segregate primary breast 
tumors according to their likelihood of giving rise to 
metastases in patients (Chang et al., 2004). This may 
simply reflect the reaction of the stroma to an aggressive 
tumor, or it might indicate that a tumor’s aggressiveness 
is influenced by the composition and activity of its stro-
mal infiltrate. Indeed, how cancer-associated fibroblasts 
contribute to metastatic progression is under intense 
investigation. One piece of the puzzle involves the pro-
duction of the chemokine CXCL12 by breast cancer-
associated fibroblasts (Allinen et al., 2004; Orimo et al., 
2005). Upon examination in xenograft and in vitro mod-
els, CXCL12 augmented the proliferation and migratory 
activity of tumor cells while concomitantly facilitating 
angiogenesis in developing tumors. The latter was partly 
mediated by the recruitment of circulating endothelial 
progenitor cells expressing CXCR4, which is the recep-
tor for CXCL12 (Figure 3) (Orimo et al., 2005). Insights 
like this into mesenchymal facilitation of metastatic pro-
gression may identify promising new approaches for 
cancer therapy.
Other cell types that are frequently present in 
tumors include leukocytes and lymphocytes that may 
be recruited there as a physiological response to tis-
sue injury. Natural killer cells, antigen presenting cells, 
and different subclasses of T and B lymphocytes are 
in charge of the immune attack and are thus in general 
tumor suppressive. However, this potent response is 
frequently blunted during the progression of neoplasms 
by the tumor-derived overexpression of immunosup-
pressive cytokines such as TGF-β, interleukin-10, and 
interleukin-23 (Gorelik and Flavell, 2002; Langowski et 
al., 2006; Zou, 2005). Furthermore, tumor cells may not 
provide the costimulatory signals necessary to elicit a 
robust immune response, such as those that neutral-
ize the autoinhibitory activity of cytotoxic-T lymphocyte 
antigen-4, CTLA-4 (Chambers et al., 2001).
Specific contributions of the innate immune response 
to tumor development and progression are complex and 
have been the subject of several recent reviews (Cond-
eelis and Pollard, 2006; de Visser et al., 2006). Overall, 
the cells and cytokines that mediate chronic inflamma-
tion facilitate both tumor initiation and metastatic pro-
gression. Some of the metastasis-promoting effects 684 Cell 127, November 17, 2006 ©2006 Elsevier Inc.may impinge on cytokine-mediated activation of the 
nuclear factor kappa B (NF-κB) pathway in tumor cells 
(Karin, 2006). Additionally, the synthesis of prostag-
landins by inflammatory cells expressing the inducible 
cyclooxygenase 2 (COX-2) may also participate in meta-
static progression (Dannenberg and Subbaramaiah, 
2003; Minn et al., 2005a). At the cellular level, tumors 
that have been infiltrated by activated macrophages 
typically follow an aggressive course of disease (Cond-
eelis and Pollard, 2006). Attracted to regions of hypoxia 
and necrosis, tumor-associated macrophages potently 
induce angiogenesis by secreting copious amounts of 
vasoactive factors (e.g., VEGF, IL-8, and PGE2), as well 
as proteases that enhance their bioactivity (e.g., MMP-
9 and uPA) (Condeelis and Pollard, 2006). Additionally, 
macrophages release several growth factors (e.g., EGF, 
PDGF, and HGF) that may facilitate tumor-cell prolifera-
tion, survival, and invasion during cancer progression 
(Condeelis and Pollard, 2006). Mice with defects in the 
macrophage lineage due to mutations in CSF-1 rarely 
develop lung metastases from aggressive polyoma mid-
dle T-driven mammary tumors (Condeelis and Pollard, 
2006). Modulation of the metastatic phenotype through 
targeted intervention of specific branches of the innate 
immune response remains a promising future area of 
cancer therapy.
Highways to Distant Organs
In order to metastasize, cancer cells must invade tumor-
associated vasculature to gain access to distant sites 
in the body. This is facilitated by the need of develop-
ing tumors to establish neo-vasculature in order to 
grow beyond the diffusion limit of preexisting blood 
vessels (Hanahan and Folkman, 1996). The acquisition 
of this angiogenic phenotype—termed the “angiogenic 
switch”—represents a vital step in the evolution of solid 
tumors (Hanahan and Folkman, 1996). This event occurs 
partly through induced outgrowth of the preexisting vas-
culature and partly through de novo recruitment of vas-
cular cell precursors from the circulation. Lymphangio-
genesis is also observed in advanced primary cancers. 
This results in a tortuous network of lymphatic vessels 
designed to collect interstitial fluid effusions and carry 
them to lymph nodes and subsequently into hematog-
enous circulation (Alitalo et al., 2005). Perhaps because 
lymphatic vessels are more leaky in their design than 
blood vessels—owing to the lack of tight intercellu-
lar junctions between lymphatic endothelial cells—the 
presence of lymph-node metastasis often represents 
an early prognostic indicator of tumor invasiveness 
and metastatic dissemination in several types of carci-
noma and in melanoma (Alitalo et al., 2005). However, 
other metastatic malignancies, such as sarcomas, are 
notorious for metastasizing to distant sites without any 
prior evidence of local spread to regional lymph nodes. 
Regardless, it is thought that access to all organs of the 
body (lymph nodes excluded) is predominantly through 
the hematogenous circulation.
The molecular mechanisms controlling intravasation 
(the penetration of the blood vessels by invading tumor 
cells) remain to be defined. In a recent study of genes 
involved in lung metastasis of a mouse mammary tumor 
cell line, enhanced expression of Twist—a transcription 
factor that promotes EMT transitions—was found to favor 
metastasis due to its ability to augment the rate of hema-
togenous intravasation (Yang et al., 2004). It remains 
unknown whether this effect was due to the acquisition 
of specific biological functions that enabled breach of the 
endothelial vasculature or was an indirect consequence 
of the enhanced motility of cancer cells with mesen-
chymal attributes. It is possible that once cancer cells 
become highly motile within primary tumors, they are 
naturally attracted to blood vessels due to chemoattrac-
tive gradients and extracellular matrix tracks emanating 
from (or terminating) there. Indeed, this was observed in 
the intravital imaging studies of experimental mammary 
carcinomas (Condeelis and Segall, 2003). Technological 
advances that enable the isolation and genomic analysis 
of circulating cancer cells from patients and in experi-
mental tumor models may yield novel insights into the 
molecular prerequisites of malignant intravasation.
Life in Transit
Once malignant cells have invaded this circulatory com-
partment, they attain ready access to virtually all organs 
of the body (Figure 3). However, they must be able to 
survive several stresses, including physical damage 
from hemodynamic shear forces, and immune-mediated 
killing. Recent advances have begun to make headway 
into the mechanisms that allow metastatic cells to evade 
these perils.
Circulating tumor cells may promote their survival 
by co-opting blood platelets, using them as shields. 
Clinically observed for well over a century, malignan-
cies have a tendency to induce a hypercoagulable state 
in their hosts (Nash et al., 2002). Histopathological 
analysis of early-stage hematogenous metastases in 
humans frequently reveals the coexistence of throm-
bosis, with abundant fibrin deposition (Ruiter et al., 
2001). Disrupting the interaction between tumor cells 
and platelets in experimental models has validated this 
relationship as causal for metastasis to multiple target 
organs (Nash et al., 2002). Consequently, tumor emboli 
are believed to possess greater metastatic potential 
than naked tumor cells, owing at least in part to their 
resistance to immune-mediated mechanisms of clear-
ance and to physical hemodynamic forces (Nash et al., 
2002). Understanding the detailed mechanisms that 
underlie tumor-cell and platelet adhesion and interac-
tion, as well as selective ways of inhibiting them without 
disrupting physiological hemostasis, may translate into 
promising antimetastasis therapies when initiated early 
in the course of disease progression.
Consideration has also been given to mechanisms 
that may allow evasion of cell death that is induced by 
the loss of adhesive supports (referred to as anoikis). The brain-derived neurotrophic factor (BDNF) recep-
tor trkB conferred resistance to anoikis to immortal-
ized cells in vitro and increased the metastatic activ-
ity of a rat intestinal epithelial cell line (Douma et al., 
2004). However, the relevance of anoikis in the proc-
ess of metastasis remains uncertain. In humans, it 
may take mere minutes for a malignant cell departing 
from a primary tumor to encounter a capillary bed and 
adhere to the vascular wall. If the time that circulat-
ing tumor cells spend devoid of adhesion is so short, 
anoikis may not be a very significant impediment dur-
ing the physiological progression of metastasis. As 
mentioned earlier, resistance to death from detach-
ment may be more relevant at earlier stages of the 
metastatic cascade.
Rapid mechanical lodging in capillaries and associa-
tion with platelets are likely a prevalent form of tumor 
cell entrapment in distant organs. However, it is also 
possible that the initial homing of disseminated cancer 
cells to a secondary organ involves adhesive interac-
tions between cell-surface receptors expressed on 
malignant cells and their cognate ligands expressed 
in various target sites for metastasis. Integrin recep-
tors have been proposed to participate in such homing 
interactions. For example, α3β1 integrins expressed on 
circulating tumor cells have been shown to bind to lam-
inin-5 within exposed regions of the vascular basement 
membrane during lung metastasis (Wang et al., 2004). 
Using a phage display screening approach, a novel 
adhesion receptor was identified and named metad-
herin, which was found to be expressed by metastatic 
breast cancer cells and binds to an as of yet unchar-
acterized ligand expressed selectively on lung-capil-
lary endothelial cells (Brown and Ruoslahti, 2004). In 
addition to adhesion receptors, chemokines and their 
receptors have also been implicated in metastatic-cell 
homing to target tissues. For example, CXCR4 expres-
sion in breast cancer cells was shown to be important 
for metastasis to CXCL12-rich tissues, such as the 
lungs (Muller et al., 2001). These and other receptor-
ligand pairs may account for some of the heterogeneity 
in target-tissue homing exhibited during metastatic dis-
semination of different primary tumors.
Getting out: Extravasation
Having invaded and endured the circulation, meta-
static cells must at some point escape once again, 
but this time out of the endothelial vasculature and 
into a target tissue in a process called extravasation 
(Figure 3). Exactly when this event occurs in the cas-
cade of metastasis may vary from tumor to tumor. In 
some cases, considerable growth within the intra-
vascular space may occur until the lesion physically 
bursts through the limiting surrounding vasculature 
(Al-Mehdi et al., 2000). The cytoskeletal anchoring 
protein ezrin may facilitate this escape in metastatic 
osteosarcoma cells. Inhibiting ezrin’s expression 
in these cells resulted in higher rates of cancer-cell Cell 127, November 17, 2006 ©2006 Elsevier Inc. 685
death prior to metastatic extravasation into the lung 
parenchyma (Khanna et al., 2004).
Are there signals emanating from metastatic cells that 
actively induce changes in the vascular permeability of 
blood vessels in target organs? VEGF—initially identi-
fied as a potent vascular permeability factor—is one 
prime candidate (Weis and Cheresh, 2005). The activa-
tion of Src family kinases in endothelial cells exposed to 
VEGF induces disruptions in endothelial cell junctions, 
which can facilitate metastatic extravasation. Consistent 
with this, Src knockout mice were protected from lung 
metastatic colonization by VEGF-secreting cancer cells 
(Criscuoli et al., 2005). Further exploration of molecular 
players mediating this potentially rate-limiting step of 
metastatic progression will determine if it occurs within 
a therapeutically susceptible time frame.
Figure 4. Patterns of Metastatic Colonization 
Circulating tumor cells are confronted by nonreceptive secondary 
organ sites. Each of these sites exhibits properties that make it dis-
tinct from the organ from which the malignant cells disseminated. To 
successfully colonize a secondary site, metastatic cells must adopt 
a signaling vocabulary that is appropriate for the extrinsic microen-
vironment. Because different organs will place different demands on 
the invading tumor cells, there will be selection for distinct mediators 
of metastatic colonization. These concepts have been demonstrated 
through analysis of a heterogeneous population of breast-cancer 
cells derived from pleural effusions in a patient with widely metastatic 
breast cancer. In vivo selection for specific metastatic tropisms us-
ing immunocompromised mice has yielded cellular subpopulations 
with highly enriched metastatic activity to the brain, lungs, and bone. 
Metastatic activity was visualized using bioluminescent imaging. As 
expected, the genes that mediate these aggressive site-specific met-
astatic activities are largely distinct.686 Cell 127, November 17, 2006 ©2006 Elsevier Inc.Patterns of Colonization
The organ distribution of full-blown metastases from a 
primary tumor is not random (Figure 4). After analyzing 
secondary cancer outgrowths in a series of autopsies 
for breast-cancer victims, Stephen Paget proposed 
that disseminated cancer cells, or “seeds,” would 
only colonize organ microenvironments, or “soils,” 
that were compatible with their growth (Paget, 1889). 
Clinical observation of cancer patients supports the 
notion that circulatory patterns alone provide only a 
partial explanation for preferred sites of metastasis 
(Fidler, 2003). For example, systemic breast cancer 
frequently metastasizes to the lungs, bones, liver, and 
brain—most of which do not have a direct circulatory 
connection to breast tissue. Advanced prostate can-
cer has a more selective pattern of metastatic recur-
rence, with bone being the predominant site, whereas 
visceral organs such as the lungs or liver are much 
more rarely involved. Uveal melanomas metastasize 
with astonishing specificity to the liver—and sarcomas 
to the lungs.
One prediction of Paget’s seed-and-soil hypothesis is 
that metastatic cells will only colonize compatible tar-
get tissues, even if they are artificially targeted in large 
numbers to inhospitable sites. A demonstration of this 
phenomenon in humans was serendipitously obtained 
in ovarian-cancer patients that received palliative perito-
neovenous shunting of their ascites fluid into the jugular 
vein (Tarin et al., 1984). Intended to relieve the pain and 
discomfort of malignant ascites without causing meta-
bolic imbalances that arise from direct removal of large 
quantities of peritoneal fluid, this procedure inadvert-
ently allowed the release of millions of metastatic can-
cer cells directly into the venous circulation of cancer 
patients over the remainder of their lives. Astonishingly, 
the majority of patients did not develop disseminated 
metastases, sometimes even after two years of continu-
ous vascular shunting. Furthermore, even when metas-
tases were observed after autopsy, they were frequently 
indolent growths.
What are the molecular and cellular determinants of 
unique metastatic tropisms? Recent advances have 
brought us closer to understanding the molecular and 
cellular bases for this important aspect of metastasis. 
It is now appreciated that at least two classes of deter-
minants affect site-specific metastatic outgrowth. First, 
there must be an initiation of a viable premetastatic 
niche within the target organ—one that facilitates the 
initial survival of extravasated tumor cells in a nonrecep-
tive target organ. Subsequently, the invading metastatic 
cell must display the appropriate functions to effectively 
colonize the new site.
Generating a Viable Niche
A novel mechanism for metastatic initiation has recently 
been proposed, which involves mobilization of hemat-
opoietic progenitors from the bone marrow via circula-
tion and into target sites for metastatic colonization in 
response to hormonal factors emitted by primary tumors 
(Kaplan et al., 2005). Molecular characterization of these 
recruited hematopoietic cells identified them as express-
ing VEGFR1, CD133, CD34, and c-kit. These cells homed 
to and preconditioned sites of metastasis prior to dis-
semination of tumor cells from the primary site. Targeted 
inhibition of VEGFR1-expressing progenitors using 
neutralizing antibodies suggested that this precondi-
tioning was necessary for metastatic progression. Fur-
thermore, a subcutaneously inoculated lung carcinoma 
that induced these bone marrow-derived progenitors to 
congregate only in the lungs also metastasized only to 
that site, whereas a melanoma that recruited these pro-
genitors to multiple organ sites exhibited a widespread 
metastatic tropism. Thus, cellular preconditioning by 
bone-marrow cells seems to contribute to organ-spe-
cific metastatic behavior.
What are the mechanisms of hematopoietic progenitor 
recruitment, and what does metastatic preconditioning 
entail? Although answers are pending, mice expressing 
a kinase-dead VEGFR1 have a decreased susceptibil-
ity to experimental lung metastases deriving from an 
implanted primary tumor (Hiratsuka et al., 2002). In this 
study VEGFR1 signaling was required for the premeta-
static induction of MMP9 expression in endothelial 
cells and macrophages of the lungs by distant primary 
tumors (Hiratsuka et al., 2002). This premetastatic 
induction of MMP9 in the lung was postulated to condi-
tion the lung microenvironment to be more compliant for 
the invasion of metastatic cancer cells upon their arrival 
from circulation. Thus, VEGFR1 ligands and the down-
stream signals that they propagate may be required for 
the tumor-dependent recruitment of macrophage-like 
bone-marrow progenitors and/or for their premetastatic 
conditioning of target organ sites. Although several open 
questions still exist, this pathway exemplifies an impor-
tant noncell autonomous aspect of metastasis and high-
lights the diversity of mechanisms involved.
In a State of Dormancy
The vast majority of tumor cells that have undergone 
extravasation still are not able to effectively colonize 
the new site. For several types of carcinomas, solitary 
tumor cells can be detected in the bone marrow years 
before the development of overt metastasis (Braun et al., 
2005). The existence of such minimal residual disease 
(MRD) represents a predictive factor for disease recur-
rence and overall survival and is similar to lymph-node 
metastasis as an indicator of systemic disease (Pantel 
and Brakenhoff, 2004). Regardless, most of these cells 
will fail to convert into macrometastases.
What are the rate-limiting factors that leave tumor cells 
in a state of dormancy? Are these dormant cells the same 
ones that later give rise to overt metastases? What are 
the genetic and epigenetic dynamics of solitary dissemi-
nated cells? To answer some of these questions, experi-
mental models of metastasis have been exploited. At 
least in some situations, an inability to induce angiogen-esis at a secondary site appears to limit the outgrowth of 
micrometastases (Chambers et al., 2002). In this context, 
the acquisition of an angiogenic stimulus that is effective 
in the relevant secondary microenvironment could break a 
dormant state that is imposed by limited access to blood 
vessels. In other cases, however, disseminated tumor 
cells remain dormant in microenvironments where angio-
genesis does not appear to be rate limiting. For reasons 
that are unclear, these solitary disseminated tumor cells 
are viable yet unable to re-enter the cell cycle. Perhaps 
due to their quiescence, adjuvant chemotherapy does not 
eradicate these solitary cells in breast-cancer patients 
(Pantel and Brakenhoff, 2004). Nonetheless, when simi-
lar dormant cells were extracted from liver tissue in a 
mouse model of breast cancer and reimplanted into the 
mammary fat pad, they were capable of forming tumors 
(Chambers et al., 2002). Dormant cells extracted from the 
bone marrow of cancer patients also possess a prolifera-
tive potential when plated in vitro, but to various degrees 
(Solakoglu et al., 2002). This heterogeneity in ex vivo pro-
liferative potential is clinically significant: patients harbor-
ing MRD cancer cells that were more efficiently able to 
re-enter the cell cycle had a poorer survival than patients 
with MRD consisting of more quiescent cells (Solakoglu 
et al., 2002). Collectively, these findings suggest that dis-
seminated tumor cells might enter a state of cell-cycle 
arrest, possibly induced by incompatibilities between the 
cancer cells and the secondary soil(s). Recall that, to a 
wandering cancer cell, no soil is really friendly but only 
tolerant at best.
Recent genomewide analyses of single cells are 
bringing the field closer to understanding the dynam-
ics of MRD as it progresses into full-blown metasta-
sis. The application of these technologies to dissemi-
nated cells from patients in defined stages of cancer 
progression has implicated dissemination as an early 
event in a cancer’s history—after the onset of genomic 
instability but before the rampant imbalances evident 
during and after telomeric crisis (Pantel and Braken-
hoff, 2004). The transition from MRD to overt metas-
tasis in human breast, prostate, and gastrointestinal 
carcinomas has been proposed to coincide with the 
selective expansion of rare clones with distinct profiles 
of cytogenic abnormalities (Klein et al., 2002). Being 
able to dissect the genetic and epigenetic dynamics 
underlying the transition from dormancy to metasta-
sis will be instrumental in advancing this area of study 
that, although technically difficult, is central to under-
standing metastasis.
Becoming Organ Specific
To escape dormancy or to colonize a new organ outright, 
disseminated tumor cells must have the capacity to pro-
ductively interact with the new microenvironment in order 
to extract growth and survival advantages. Because dif-
ferent organ microenvironments may impose distinct 
requirements on cancer cells for full-blown coloniza-
tion, the mediators of organ-specific metastasis may not Cell 127, November 17, 2006 ©2006 Elsevier Inc. 687
always be the same (Figure 4). Mechanistic dissection 
of secondary organ colonization in model systems has 
begun to identify sets of mediators that may be neces-
sary to complete this late stage of metastatic progres-
sion (Figure 5).
Figure 5. Site-Specific Mediators of Metastasis
(A) Conceptual categories of functions associated with site-specific 
metastasis genes. Factors in the microenvironment may directly act 
on malignant tumor cells (1) to modulate a cell-intrinsic property 
(such as self renewal) or to regulate transcription of other metastasis 
mediators. Tumor cells may express homing receptors (2) that rec-
ognize ligands present in the stroma of the metastatic microenviron-
ment. Metastatic cells may release extracellular modifying effectors 
(3), such as proteases, to remodel the surrounding milieu to accom-
modate cellular invasion. Growth factors may be secreted by tumor 
cells to act on stromal cells in the local microenvironment (4) or at 
a distance (5). Associated stromal cells in the metastatic microenvi-
ronment may actively contribute to several of these mechanisms, as 
depicted in the diagram. 
(B) A partial listing of known cellular and molecular players involved 
in osteolytic bone metastasis. The release of TGFβ from dissolved 
bone matrix drives further expression of some metastasis mediators, 
establishing what is commonly referred to as the “vicious cycle of 
bone metastasis.”688 Cell 127, November 17, 2006 ©2006 Elsevier Inc.Colonizing Bone
The best characterized example of reciprocal cellular and 
molecular adaptations that occur between cancer cells 
and their stroma during site-specific metastatic pro-
gression comes from the analysis of tumors that metas-
tasize to bone. A frequent site of distant metastasis, the 
skeletal system is composed of diverse cell types. When 
metastatic breast cancer invades bone, it frequently 
presents clinically with painful fractures due to induced 
hyperactivation of bone-resorbing osteoclasts (Mundy, 
2002). Advanced prostate cancer, to the contrary, pre-
dominantly involves the stimulation of bone-depositing 
osteoblasts—thus resulting in a net increase in bone 
density and eventual bone-marrow displacement (Logo-
thetis and Lin, 2005). What enables metastatic cells to 
colonize the unique bone microenvironment, and what 
determines whether the lesion will be primarily osteolytic 
or osteoblastic? Years of careful modeling and mecha-
nistic dissection of breast- and prostate-cancer bone 
metastasis have shed light on these questions.
Bone homeostasis is preserved through a balance 
between osteoblasts and osteoclasts. A highly con-
served molecular circuitry maintains this balance under 
normal conditions and after acute injury. Regulatory 
signals can come from afar, such as calcitonin and par-
athyroid hormone, or they can originate locally within 
the bone to directly modulate the differentiation and 
activity of bone-remodeling cells (Harada and Rodan, 
2003). Genetic studies have linked Wnt and BMP sig-
nals to the differentiation of osteoblasts from bone-mar-
row mesenchymal precursors, perhaps in part through 
the induction of Runx2, a “master” transcription factor 
in the osteoblast lineage (Harada and Rodan, 2003). 
Osteoclasts, derived from the monocytic branch of 
hematopoiesis, can be differentiated and stimulated 
through the expression of cytokines, including M-CSF, 
RANKL, IL-6, IL-8, and IL-11 (Boyle et al., 2003). The 
source for many of these factors, especially RANKL, is 
in fact the bone-forming osteoblasts—thus establish-
ing a cellular and molecular cycle for local bone home-
ostasis (Mundy, 2002).
Cancer cells that successfully metastasize to bone 
invariably hijack these conserved physiological mech-
anisms. Whereas prostate cancer cells frequently 
secrete osteoblast-promoting factors, including BMPs, 
Wnt-family ligands, endothelin-1, and PDGF, osteolytic 
breast-cancer cells frequently inhibit these pathways 
by secreting soluble inhibitors while overexpressing 
osteoclast-inducing factors such as PTHrP (parathy-
roid hormone-related protein), IL-8, and IL-11 (Logo-
thetis and Lin, 2005; Mundy, 2002). In addition, there is 
frequent disruption of the homeostatic RANK-RANKL 
loop between osteoclasts and osteoblasts. Metastatic 
prostate carcinomas can secrete high amounts of the 
RANKL inhibitor osteoprotegerin, thereby attenuat-
ing osteoclastic reactions during metastasis (Logothe-
tis and Lin, 2005). Conversely, osteolytic cancer cells 
can secrete proteases that cleave RANKL into a more 
active form, thereby activating the osteoclasts (Lynch et 
al., 2005). Moreover, because bone is a rich source of 
matrix-embedded growth factors such as IGF and TGF-
β, these cytokines are released upon osteolysis and act 
upon the invading tumor cells to promote the induction 
of osteoclast-promoting factors (Kang et al., 2005; Kang 
et al., 2003; Mundy, 2002; Yin et al., 1999). This posi-
tive feedback loop, referred to as “the vicious cycle of 
osteolytic bone metastasis,” may indeed be the driving 
force for the selection of osteolytic mechanisms during 
the development of bone metastases.
In a genomewide analysis of genes selected for dur-
ing bone metastatic progression in a breast-cancer 
xenograft model, several microenvironmental regulators 
were identified that suggested diverse biological func-
tions (Kang et al., 2003). These included the homing 
and survival chemokine receptor CXCR4, the extracel-
lular modifiers osteopontin and CTGF (connective tissue 
growth factor), the matrix metalloprotease MMP1, and 
the osteoclastogenic cytokine IL-11 (Figure 5). Interest-
ingly, this bone-metastasis signature was manifest in 
rare pre-existing clones within the unselected malignant 
cell population, which itself expressed genetic markers 
indicative of general metastatic potential (Kang et al., 
2003). Indeed, the parental cell line was a heterogeneous 
cellular outgrowth derived from the pleura of a patient 
with disseminated breast cancer, which was comprised 
of cells exhibiting diverse site-specific metastatic poten-
tial when xenografted into immunocompromised mice 
(Minn et al., 2005b). This heterogeneity in metastatic 
potential—a hallmark of cells from advanced breast-
cancer patients—could not be explained by even sub-
tle differences in expression of a previously described 
“poor prognosis signature” (Minn et al., 2005b). These 
observations are in line with the seed-and-soil hypoth-
esis in that metastatic colonization of a secondary organ 
requires multifunctional site-specific metastasis pro-
grams above and beyond those genes that may promote 
general metastatic potential.
Colonizing the Lungs
Pulmonary involvement is relatively common among 
patients with metastatic disease of many different types 
of primary tumors, including breast cancer, gastroin-
testinal tumors, melanoma, sarcoma, and kidney can-
cer. A partial explanation for this high prevalence may 
be that our entire cardiac output circulates through the 
lung-capillary network. Most commonly, lung metastatic 
lesions initiate at the level of small pulmonary arteri-
oles, where they must either burst through or otherwise 
breach both the tight endothelial junctions of lung blood 
vessels and the underlying basement membrane. Once 
in the lung parenchyma, metastatic cells must survive 
and grow in this unique microenvironment, which con-
tains highly organized extracellular matrix and special-
ized cell types for the purpose of respiration.
Many mouse models of cancer have been used for the 
study of lung metastasis. However, the clinical relevance 
of these models is not always apparent, especially when large numbers of cancer cells are inoculated directly into 
the venous circulation to force the seeding of the lungs. 
For this reason, it is important to validate the physiologi-
cal relevance of mediators of metastasis identified using 
orthotopic models, as well as through the analysis of 
clinical specimens of primary tumors and metastases.
In pediatric sarcomas, the cytoskeletal anchoring pro-
tein ezrin appears to be facilitate tumor-cell extravasa-
tion into the lung parenchyma, and its expression cor-
relates negatively with overall survival in osteosarcoma 
patients (Khanna et al., 2004). Expression analysis of 
clinical samples of primary and lung metastatic hepa-
tocellular carcinoma (HCC) identified osteopontin as a 
candidate mediator that was validated through inhibitor 
studies in experimental models of HCC metastasis (Ye 
et al., 2003). In breast cancer, the TGFβ and NF-κB path-
ways have been implicated in lung metastasis, although 
the downstream mediators remain largely unknown (Luo 
et al., 2004; Siegel et al., 2003). Recently, examination of 
genes selected in vivo during lung metastasis of breast-
cancer cells identified a gene-expression signature that 
was highly enriched in mediators of pulmonary metasta-
sis. This diverse set of genes encoded for secreted fac-
tors (including epiregulin, CXCL1, and SPARC), cell-sur-
face receptors (e.g., VCAM1 and IL13Rα2), extracellular 
proteases (e.g., MMP1 and MMP2), and intracellular 
effectors (e.g., Id1 and COX2), which cooperated to pro-
mote lung metastasis. Significantly, these genes were 
further validated in a cohort of primary breast tumors, 
where expression of these genes correlated with lung 
metastatic relapse in the corresponding patients. Intrigu-
ingly, the lung metastasis genes identified in this study 
were largely distinct from genes previously associated 
with metastasis to bone through in vivo selection from 
the same parental breast-cancer cell line (Minn et al., 
2005a). This observation may reflect the different func-
tions necessary to colonize the biologically disparate 
bone and lung microenvironments.
Colonizing the Brain
Metastatic colonization of the brain, although less fre-
quent than metastasis to other organs, bodes an alarm-
ingly poor prognosis. Primary tumors that metastasize to 
the brain include lung cancer, breast cancer, melanoma, 
renal carcinoma, and colon cancer. Metastatic cells may 
either colonize the brain parenchyma or thrive along the 
leptomeninges, which represents the most aggressive 
form of this disease. Vascular access to the central nerv-
ous system is tightly regulated through a specialized 
structure termed the blood brain barrier (BBB). The BBB 
is composed of tightly adjoined endothelial cells that are 
further lined by basal lamina and astrocyte foot proc-
esses (Abbott et al., 2006). Physiologically, this barrier 
is so restrictive that even serum proteins are excluded 
unless they are actively shuttled across by intracellular 
transport. During brain metastasis, the BBB must be 
compromised in order to allow extravasation of cancer 
cells. Once in the brain parenchyma, interactions with 
glial cells may further influence the ability of a metastatic Cell 127, November 17, 2006 ©2006 Elsevier Inc. 689
cell to colonize it. Unfortunately, due to a dearth of reli-
able experimental models of brain metastasis, relatively 
little is known about mechanisms that enable brain colo-
nization in mouse models, and even less so is known 
about what causes it in man.
Colonizing the Liver
The liver is a densely vascularized tissue that is supplied 
by both the portal and systemic circulatory systems. 
Advanced gastrointestinal malignancies tend to metas-
tasize first to the liver, presumably due to direct per-
fusion through the portal vein. Other primary tumors can 
metastasize to the liver through the systemic vasculature, 
including breast cancer, uveal melanoma, and lung can-
cer. Unlike the restrictive blood vessels that perfuse the 
lungs and brain, hepatic sinusoids are discontinuously 
lined with endothelial cells, making them highly porous 
to blood nutrients and circulating cells. For this reason, 
extravasation may not be a major barrier to liver metas-
tasis, as was observed in quantitative cell-tracking stud-
ies in an experimental mouse model (Chambers et al., 
2002). Rather, invasion into the hepatic parenchyma and 
Figure 6. Impact of Cell of Origin on Metastatic Outcome
(A) Owing to differing predispositions encoded in cells with distinct 
developmental origins, the same oncogenic alterations may lead to 
diverse metastatic outcomes. In some cases, no metastatic behavior 
may be coupled to oncogenic transformation. In other instances, me-
tastases might arise but may occur to different organs depending on 
which predisposing effectors are expressed. 
(B) Two different tumor types may metastasize to the same second-
ary organ, such as breast and lung carcinomas metastasizing to the 
brain. It is currently unknown whether the developmental history of a 
cancer would result in different or common mediators of site-specific 
metastasis. Predisposing factors related to the cell of origin may en-
gender different rate-limiting barriers during brain metastatic progres-
sion. Alternatively, different epigenetic accessibilities of the breast or 
lung cancer genomes may influence the likelihood of activating any 
particular genetic mediator of metastatic activity—ultimately result-
ing in unique genetic solutions to metastatic progression to the same 
secondary site.690 Cell 127, November 17, 2006 ©2006 Elsevier Inc.avoidance of cell death from resident immune cells may 
be rate-limiting steps during metastatic colonization of 
the liver. Indeed, expression of the hepsin protease was 
sufficient to enable liver metastasis of prostate-cancer 
cells in a transgenic mouse model without affecting pro-
liferation of the primary tumor (Klezovitch et al., 2004). 
Additionally, periostin-mediated promotion of Akt sig-
naling and cell survival in metastatic cells (Bao et al., 
2004), as well as neutralization of proapoptotic TRAIL 
expression on natural killer (NK) cells resident in the liver 
(Takeda et al., 2001), are both mechanisms that facilitate 
hepatic metastasis in mouse models.
Seeding and Reseeding
Analysis of the aforementioned lung metastasis gene 
signature in a cohort of primary breast cancers using 
microarrays revealed a surprising result: some of the 
genes that promote metastasis were coexpressed within 
a subset of primary tumors (Minn et al., 2005a). Why 
would genes associated with and mediating aggres-
sive lung metastasis from circulatory inoculation in mice 
be expressed in primary tumors to an extent that was 
detectable by microarray profiling? Orthotopic implan-
tation into the mammary glands of mice revealed that 
cells expressing the lung metastasis genes generated 
primary tumors that grew more rapidly than the corre-
sponding parental cell line (Minn et al., 2005a). Moreo-
ver, histological markers of cellular proliferation were 
unchanged, suggesting that this augmented growth was 
not simply a consequence of accelerated progression 
through the cell cycle.
One possible explanation for these phenomena may 
be that some of the genes that mediate metastasis 
have dual functions. That is, although these genes 
promote metastatic colonization, they may have been 
selected in the primary tumor for a function that pro-
vided a selectable growth advantage in the primary 
tumor microenvironment. Alternatively, it is possible 
that the properties conferred by metastasis-promot-
ing genes—such as migratory capacity, proteolytic 
activity, self renewal, and extravasation—may, in and 
of themselves, allow for the progressive enrichment of 
cellular subpopulations exhibiting them in a primary 
tumor. For example, metastatically primed cells being 
shed at high rates from a primary tumor or from devel-
oping metastases may, at some finite frequency, travel 
back to the primary tumor. The intrinsic colonizing 
functions of such cells may allow them to constantly 
reseed the primary tumor—in effect metastasizing to 
their site of origin. It has been speculated on theo-
retical grounds that this would provide an effective 
means to achieve accelerated tumor growth (Norton 
and Massagué, 2006). If true, this phenomenon would 
partly explain why genes that promote metastasis are 
frequently expressed in primary tumors and why there 
is a consistent link between large tumor size, rapid 
growth rate, and metastatic behavior in a majority of 
cases of clinical cancer.
Impact of the Cell of Origin
Despite having gleaned some of the molecular underpin-
nings of organ specificity, we are still left pondering why 
different types and subtypes of cancer have varied pro-
pensities for metastasis, sometimes to specific second-
ary sites. Consideration of the original predisposition of 
the transformed cell of origin suggests several discrete 
possibilities that may explain these phenomena (Figure 
6). Certain cell lineages may express molecules that 
bias the metastatic efficiency to different target organs. 
For example, normal mammary epithelial cells, as well 
as their cancerous counterparts, express RANK—the 
receptor for the previously discussed osteoclast dif-
ferentiation factor RANKL. A recent study suggests 
that this receptor-ligand combination may predispose 
breast-cancer cells to bone colonization (Jones et al., 
2006).
The developmental history of a cell may also predis-
pose it to activate expression of specific metastasis-pro-
moting mechanisms upon malignant transformation. This 
phenomenon has recently been demonstrated through 
the use of defined oncogenic elements to transform 
multiple normal human cell types into their cancerous 
counterparts, which are capable of generating tumors in 
immunocompromised mice (Gupta et al., 2005). Notably, 
whereas tumors derived from transformed fibroblasts 
and mammary epithelial cells were universally nonmeta-
static, tumors generated from transformed melanocytes 
metastasized aggressively to secondary sites that are 
commonly affected in patients with malignant melanoma 
(Gupta et al., 2005). This difference was attributed to the 
selective expression of the transcription factor Slug in 
transformed melanocytes but not in transformed fibrob-
last or mammary epithelial cells. Slug is a developmen-
tal mediator of high migratory activity in the melanocytic 
precursors, neural crest cells.
How the developmental history of a cell influences the 
likelihood of expressing specific mediators of metas-
tasis (such as Slug in melanoma) remains to be estab-
lished. One possibility is that lineage-specific signaling 
and transcription-factor circuitries may alter the cellular 
response to the same oncogenic alterations. Alterna-
tively, variegation in putative metastasis gene expression 
may be determined by developmentally imprinted tran-
scriptional accessibility of the transformed cell genome. 
Epigenetic modifiers, including covalent histone modifi-
cations, DNA methylation, microRNA-mediated repres-
sion, or others, could be at play.
The impact of developmental predisposition on meta-
static behavior is also important when transformation 
occurs at different stages within the same lineage. In 
breast cancer, for example, different cells of origin may 
partly explain the notable diversity in clinical manifes-
tations of the disease. Global transcriptomic signatures 
have segregated breast cancer into a composite of four 
to five distinct subtypes, which may be malignant ver-
sions of different stages in the mammary-gland line-
age. These signatures reveal patterns of overall meta-static likelihood and responsiveness to therapy (Perou 
et al., 2000). For example, tumors of the basal subtype 
share markers with the basal cell layer of normal mam-
mary glands—where myoepithelial- and putative-tissue 
stem cells reside—and are noted for their aggressive 
metastatic proclivities. Alternatively, “luminal A” subtype 
tumors express the estrogen receptor and other mark-
ers of luminal epithelial cells in normal breast and are 
responsive to hormonally targeted therapies. However, 
this subclassification of breast cancer into subtypes 
does not typically inform about detailed metastatic 
behavior, such as the likelihood of relapse to a particular 
organ for a given patient with clinical breast cancer.
Finally, organism level predispositions for meta-
static outcome may occur as polymorphisms or germ-
line mutations. In principle, a mutation that alters the 
expression or activity of a mediator of metastasis may 
be phenotypically silent during the reproductive years 
of an individual and would consequently not be evolu-
tionarily selected against. However, when one such indi-
vidual develops cancer, the hyperactivity of the metasta-
sis promoter may increase the likelihood that the tumor 
becomes metastatic. Support for this hypothesis has 
recently been provided using different inbred strains 
of mice that exhibit differing susceptibilities for lung 
metastasis in mammary tumors induced by the polyoma 
middle T oncogene (Park et al., 2005). Genetic mapping 
of the metastatic efficiency locus implicated a mutated 
hypermorphic allele of the GTPase-activating protein 
Sipa1 (Park et al., 2005). This discovery encourages the 
search for similar genetic associations in humans that 
might predispose individuals to an aggressive course of 
disease should they develop cancer.
Corollary and Outlook: An Evolving Framework  
for Metastasis
What began as a conceptualization of key steps and 
players involved in metastatic progression is progres-
sively developing into a mechanistically rich depiction of 
how metastasis actually proceeds. Advanced modeling 
approaches, technological ingenuity, and an emphasis 
on clinical validation have all contributed to a rapid rate 
of recent progress. We can envision metastasis as one 
possible outcome from the somatic evolution of cancer-
ous cells that have lost control over the integrity of their 
genome. The resulting cellular heterogeneity enables 
the selection for advantageous traits that allow malig-
nant cells to overcome diverse environmental defenses, 
which normally preserve tissue structure and function. 
Primary tumors that continue to thrive in spite of these 
obstacles and exhibit genetic or phenotypic features 
indicative of stromal-cell co-option are often enriched 
in cells that are primed for the metastatic cascade. As 
these tumors go on to spew cells and soluble factors into 
the circulation, the entire body becomes an evolutionary 
playing field. Until the primary tumor is diagnosed and 
surgically removed, one might even imagine a period 
of dynamic interplay between cells in the primary mass Cell 127, November 17, 2006 ©2006 Elsevier Inc. 691
and those that have already undergone dissemination. 
Subsequent to surgical resection, however, the metas-
tasis cascade falls beneath the radar. On occasion, rare 
clones from the collective pool of disseminated cancer 
cells may emerge that have adopted the requirements 
for growth in a secondary organ, one which they can 
now begin to colonize.
The stochastic nature of the metastatic cascade does 
not preclude the possibility of predicting the likelihood 
of its successful completion. By first understanding 
molecular mechanisms that facilitate metastasis—and 
subsequently observing the expression of these and 
other molecules in primary tumors and secondary sites 
of metastasis—the field has begun to assemble sets of 
genes whose expression or genomic status approxi-
mates the probability for specific metastatic outcomes. 
Importantly, we also realize that the pre-existing cellular 
state of a transformed cell—encoded genetically as well 
as epigenetically—can strongly predispose the resultant 
tumor to certain types of metastatic behaviors. Collec-
tively, by considering these diverse aspects of meta-
static progression, we have begun to understand not 
only how metastasis proceeds but also why it occurs in 
the first place.
As technologies advance and more pathways are impli-
cated in metastatic progression, it becomes increasingly 
feasible to focus on molecular mediators that withstand 
rigorous tests for clinical relevance (that is, allowing 
researchers to focus on what does cause metastasis 
rather than on what can cause it). Because different 
tumor types may carry different predispositions, it is 
important to systematically establish the mechanisms 
utilized by each. It is entirely possible that two different 
tumor types metastasizing to the same secondary organ 
may select for entirely different sets of mediators due 
to disparate predisposing factors. For similar reasons, 
metastasis from tumors in a given organ to a particu-
lar secondary site may resort to different mediators in 
a mouse model and in man. Nonetheless, by relating 
the molecules utilized in each scenario to the necessary 
metastatic functions that they confer, we imagine that 
general concepts governing metastasis will emerge.
Genomic technologies will lead to the discovery of 
more biomarkers of metastatic likelihood, which should 
make it possible to develop reliable assays with clini-
cal utility. Rigorous epidemiological practices should 
be adhered to as new genetic markers are validated. 
Recognizing the selective pressures in primary tumors 
that drive the emergence of metastatically primed cells 
might enable elucidation of signatures that are surro-
gate markers of specific prometastatic biological prop-
erties. Finally, “meta-signatures” must be designed that 
incorporate multiple prognostic gene sets into a singu-
lar assessment of the relevant biological properties of a 
malignancy as well as of its most likely course of clinical 
progression.
How can molecular insights into genes associated with 
metastasis be translated into new avenues for clinical 692 Cell 127, November 17, 2006 ©2006 Elsevier Inc.metastasis therapy? Progress in this front is dependent 
on a separation of the mediators of metastasis from the 
markers of metastatic potential and a subsequent under-
standing of the necessary biological functions that are 
being selected for. A mechanistic appreciation for how 
these genes mediate cancer-cell growth and survival, as 
well as crosstalk with stromal-cell accomplices, will be 
necessary to identify stages of metastasis that might be 
susceptible to therapeutic intervention. The translation 
of these discoveries to patients should include a pre-
liminary screening step to prospectively identify those 
cancer patients that might benefit most from any given 
targeted therapy approach. These are undoubtedly 
ambitious objectives, but the pace of recent progress 
suggests that the field is on track to making these goals 
a reality.
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